In an article published in The New Yorker, Dr. Dhruv Khullar, the Center’s director, and an associate professor of population health sciences at Weill Cornell Medical College, investigates the growing role of artificial intelligence in drug discovery. The piece examines the strengths and limitations of new machine-learning technologies, and what they could mean for the future of pharmaceutical research.
Dr. Khullar was interviewed by Ron Southwick, editor at Chief Healthcare Executive (CHE), about the risks and benefits of A.I. in health care.
Read more at CHE.